Bentham Science Publishers is pleased to announce that MicroRNA has been awarded an Impact Factor ranking by Clarivate Analytics. The journal, currently edited by Dr. Alberto Izzoti (University of Genoa), has been providing readers with cutting-edge research on molecular biology and the therapeutic applications of MicroRNAs. Bentham Science extends its heartfelt congratulations to all journal contributors, including editors, authors and staff who have supported the journal since its inception.
Impact Factor Update: With MicroRNA’s addition to the Impact Factor list, 62 Bentham Science journals now hold this prestigious distinction. Current Neuropharmacology continues to lead the list with a 2024 impact factor of 5.3, followed by Recent Patents on Anti-Cancer Drug Discovery (4.1) and Current Medicinal Chemistry (3.5). Bentham Science is committed to publishing impactful research in the years to come.
About Bentham Science Publishers: Bentham Science Publishers is a leading academic publisher that specializes in medical and general STM (Science, Technology, and Medicine) disciplines. With a diverse portfolio of over 130 hybrid and Open Access journals, Bentham Science is dedicated to disseminating high-quality research to the global scientific community. Founded in 1992, Bentham Science was established "by scientists for scientists" and has maintained an unwavering commitment to excellence. Its peer review process is among the most rigorous in the industry, with all manuscripts undergoing double blind review by a verified pool of experts.
For media inquiries, please contact: marketing@benthamscience.net
Bentham Science Publishers sincerely thanks all those who have contributed to its mission of advancing scientific knowledge while upholding the highest standards of integrity and scholarly excellence.
Updated list of Bentham Science Journals with Impact Factors:
|
# |
Journals |
IF 2024 |
|
1 |
5.3 |
|
|
2 |
4.1 |
|
|
3 |
3.5 |
|
|
4 |
3.5 |
|
|
5 |
3.3 |
|
|
6 |
3.3 |
|
|
7 |
Current Topics In Medicinal Chemistry |
3.3 |
|
8 |
3.1 |
|
|
9 |
3 |
|
|
10 |
3 |
|
|
11 |
3 |
|
|
12 |
2.9 |
|
|
13 |
2.8 |
|
|
14 |
2.6 |
|
|
15 |
Medicinal Chemistry |
2.6 |
|
16 |
2.5 |
|
|
17 |
2.5 |
|
|
18 |
2.5 |
|
|
19 |
2.3 |
|
|
20 |
2.2 |
|
|
21 |
2.2 |
|
|
22 |
Current Vascular Pharmacology |
2.1 |
|
23 |
2.1 |
|
|
24 |
2 |
|
|
25 |
Endocrine Metabolic & Immune Disorders - Drug Targets |
2 |
|
26 |
1.9 |
|
|
27 |
1.9 |
|
|
28 |
1.8 |
|
|
29 |
1.7 |
|
|
30 |
1.7 |
|
|
31 |
1.7 |
|
|
32 |
1.7 |
|
|
33 |
1.7 |
|
|
34 |
1.6 |
|
|
35 |
1.6 |
|
|
36 |
1.5 |
|
|
37 |
1.4 |
|
|
38 |
1.3 |
|
|
39 |
1.2 |
|
|
40 |
1.1 |
|
|
41 |
1.1 |
|
|
42 |
1.1 |
|
|
43 |
Recent Advances in Inflammation & Allergy Drug Discovery |
1.1 |
|
44 |
1 |
|
|
45 |
Letters In Organic Chemistry |
1 |
|
46 |
1 |
|
|
47 |
1 |
|
|
48 |
0.9 |
|
|
49 |
0.9 |
|
|
50 |
0.9 |
|
|
51 |
0.9 |
|
|
52 |
0.8 |
|
|
53 |
0.7 |
|
|
54 |
0.7 |
|
|
55 |
0.7 |
|
|
56 |
0.6 |
|
|
57 |
0.5 |
|
|
58 |
0.4 |
|
|
59 |
0.4 |
|
|
60 |
0.3 |
|
|
61 |
0.3 |
|
|
62 |
0.3 |